MX2021012870A - Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias. - Google Patents

Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.

Info

Publication number
MX2021012870A
MX2021012870A MX2021012870A MX2021012870A MX2021012870A MX 2021012870 A MX2021012870 A MX 2021012870A MX 2021012870 A MX2021012870 A MX 2021012870A MX 2021012870 A MX2021012870 A MX 2021012870A MX 2021012870 A MX2021012870 A MX 2021012870A
Authority
MX
Mexico
Prior art keywords
antibody
cumulus
differentiation
treat
autoimmunity diseases
Prior art date
Application number
MX2021012870A
Other languages
English (en)
Spanish (es)
Inventor
Jorn Drappa
Eliezer Katz
Kathleen Mckeever
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of MX2021012870A publication Critical patent/MX2021012870A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
MX2021012870A 2019-04-24 2020-04-23 Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias. MX2021012870A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962838093P 2019-04-24 2019-04-24
US201962843096P 2019-05-03 2019-05-03
US201962858495P 2019-06-07 2019-06-07
PCT/US2020/029613 WO2020219743A2 (en) 2019-04-24 2020-04-23 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (1)

Publication Number Publication Date
MX2021012870A true MX2021012870A (es) 2022-01-18

Family

ID=72940915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012870A MX2021012870A (es) 2019-04-24 2020-04-23 Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.

Country Status (12)

Country Link
US (1) US20220204617A1 (https=)
EP (1) EP3959241A4 (https=)
JP (2) JP7779738B2 (https=)
KR (1) KR20220004113A (https=)
CN (1) CN113939532A (https=)
AU (1) AU2020263418A1 (https=)
BR (1) BR112021020924A2 (https=)
CA (1) CA3136487A1 (https=)
IL (1) IL287385A (https=)
MX (1) MX2021012870A (https=)
SG (1) SG11202111429UA (https=)
WO (1) WO2020219743A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3809260A1 (de) * 2019-10-18 2021-04-21 Siemens Healthcare GmbH System und verfahren zur administration von bildgebenden geräten
WO2022006283A2 (en) * 2020-06-30 2022-01-06 Viela Bio, Inc. Methods of treating neuromyelitis optica spectrum disorder
AU2021368769A1 (en) * 2020-10-29 2023-06-08 Viela Bio, Inc. Use of an anti-cd19 antibody to treat autoimmune disease
IL308296A (en) * 2021-05-07 2024-01-01 Viela Bio Inc Use of anti-CD19 antibody to treat myasthenia gravis
CN119604305A (zh) 2022-07-27 2025-03-11 维埃拉生物股份有限公司 伊奈利珠单抗及使用其用于持续b细胞耗竭的方法
WO2024155810A1 (en) * 2023-01-20 2024-07-25 Viela Bio, Inc. Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534859B (zh) * 2006-09-08 2017-06-09 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
RU2495882C2 (ru) * 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
MX2014010987A (es) * 2012-03-12 2015-03-03 Medimmune Llc Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease

Also Published As

Publication number Publication date
WO2020219743A3 (en) 2020-12-10
JP2025157413A (ja) 2025-10-15
CA3136487A1 (en) 2020-10-29
SG11202111429UA (en) 2021-11-29
US20220204617A1 (en) 2022-06-30
EP3959241A2 (en) 2022-03-02
WO2020219743A2 (en) 2020-10-29
IL287385A (en) 2021-12-01
CN113939532A (zh) 2022-01-14
KR20220004113A (ko) 2022-01-11
BR112021020924A2 (pt) 2022-04-19
EP3959241A4 (en) 2023-01-25
JP2022529743A (ja) 2022-06-23
AU2020263418A1 (en) 2021-11-11
JP7779738B2 (ja) 2025-12-03

Similar Documents

Publication Publication Date Title
MX2021012870A (es) Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
CL2020001575A1 (es) Anticuerpos anti-trem2 y métodos relacionados.
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
BR112018072066A2 (pt) moléculas de ligação específicas para fcgamariia e uso das mesmas
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EP4371570A3 (en) Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
WO2015157252A8 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
MX383216B (es) Anticuerpos dirigidos contra la inmunoglobulina de células t y la proteína mucina 3 (tim-3).
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201890175A1 (ru) Антитела к cd40
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
MX2020013885A (es) Anticuerpos anti-cd40 para su uso en el tratamiento de enfermedades autoinmunes.
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
WO2015157238A3 (en) Binding molecules specific for il-21 and uses thereof
CL2021000146A1 (es) Anticuerpos humanizados contra psma
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
CL2021000483A1 (es) Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения